GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA investigational vaccine (GSK3844766A)

First Posted Date: 2020-12-08

Last Posted Date: 2022-06-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 126

Registration Number: NCT04657198

Locations: 🇧🇪
GSK Investigational Site, Wilrijk, Belgium

Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Other: prospective observational cohort study

First Posted Date: 2020-12-08

Last Posted Date: 2024-07-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1213

Registration Number: NCT04657211

Locations: 🇩🇪
GSK Investigational Site, Hannover, Germany

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Phase 3

Active, not recruiting

Conditions: Lung Cancer, Non-Small Cell

Interventions: Biological: Cobolimab
Biological: Dostarlimab
Drug: Docetaxel

First Posted Date: 2020-12-07

Last Posted Date: 2024-11-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 758

Registration Number: NCT04655976

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2

Active, not recruiting

Conditions: Ovarian Neoplasms
Breast Neoplasms

Interventions: Drug: Niraparib

First Posted Date: 2020-11-23

Last Posted Date: 2025-03-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT04641247

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

Phase 1

Completed

Conditions: Anaemia

Interventions: Drug: Daprodustat

First Posted Date: 2020-11-23

Last Posted Date: 2025-04-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 259

Registration Number: NCT04640311

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)

Phase 3

Completed

Conditions: Nasal Polyps

Interventions: Drug: Placebo
Drug: Mepolizumab
Drug: Standard of care

First Posted Date: 2020-10-28

Last Posted Date: 2024-11-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 169

Registration Number: NCT04607005

Locations: 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

Phase 3

Terminated

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV MAT
Drug: Placebo

First Posted Date: 2020-10-27

Last Posted Date: 2025-02-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 10578

Registration Number: NCT04605159

Locations: 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole

Phase 1

Completed

Conditions: Celiac Disease
Coeliac Disease

Interventions: Drug: GSK3915393 Capsules
Drug: GSK3915393 Solution for Infusion
Drug: Placebo capsules
Drug: Itraconazole
Other: Water
Other: Grape fruit juice